Evidence map›Paper›PMID 27903291›Full record

ArticleJournal of hematology & oncology2016

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, Kimberly H Harrington, Alex Kentsis, Robert B Gerbing, Yi-Cheng Wang, Rhonda E Ries, Susana C Raimondi, Betsy A Hirsch and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

George S LaszloClinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA.
Todd A AlonzoDepartment of Biostatistics, University of Southern California, Los Angeles, CA, USA.
Chelsea J GudgeonClinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA.
Kimberly H HarringtonClinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA.
Alex KentsisMolecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY, USA.
Robert B GerbingChildren's Oncology Group, Monrovia, CA, USA.
Yi-Cheng WangChildren's Oncology Group, Monrovia, CA, USA.
Rhonda E RiesClinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA.
Susana C RaimondiChildren's Oncology Group, Monrovia, CA, USA.
Betsy A HirschChildren's Oncology Group, Monrovia, CA, USA.
Alan S GamisChildren's Oncology Group, Monrovia, CA, USA.
Soheil MeshinchiClinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA.
Roland B WalterClinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. rwalter@fredhutch.org.

Funding

COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID27903291
PMCPMC5129595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.